US5849263A
(en)
*
|
1993-03-30 |
1998-12-15 |
Charlotte-Mecklenburg Hospital Authority |
Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
|
US5576311A
(en)
*
|
1994-11-30 |
1996-11-19 |
Pharmos Corporation |
Cyclodextrins as suspending agents for pharmaceutical suspensions
|
US5976573A
(en)
*
|
1996-07-03 |
1999-11-02 |
Rorer Pharmaceutical Products Inc. |
Aqueous-based pharmaceutical composition
|
US5955097A
(en)
*
|
1996-10-18 |
1999-09-21 |
Virotex Corporation |
Pharmaceutical preparation applicable to mucosal surfaces and body tissues
|
US5800832A
(en)
*
|
1996-10-18 |
1998-09-01 |
Virotex Corporation |
Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
|
TW503113B
(en)
*
|
1997-01-16 |
2002-09-21 |
Senju Pharma Co |
Aqueous suspension for nasal administration
|
KR100508227B1
(ko)
*
|
1997-03-14 |
2006-03-23 |
센주 세이야꾸 가부시키가이샤 |
로테프레드놀에타보네이트수성현탁액
|
US20050048102A1
(en)
*
|
1997-10-16 |
2005-03-03 |
Virotex Corporation |
Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
|
SE9704186D0
(sv)
*
|
1997-11-14 |
1997-11-14 |
Astra Ab |
New composition of matter
|
EP1050299A4
(de)
*
|
1998-01-22 |
2007-05-02 |
Santen Pharmaceutical Co Ltd |
Augentropfen aus fluorometholonsuspension
|
US6103266A
(en)
*
|
1998-04-22 |
2000-08-15 |
Tapolsky; Gilles H. |
Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
|
JP2002523475A
(ja)
*
|
1998-09-02 |
2002-07-30 |
アラーガン・セイルズ・インコーポレイテッド |
防腐したシクロデキストリン含有組成物
|
US6395746B1
(en)
|
1998-09-30 |
2002-05-28 |
Alcon Manufacturing, Ltd. |
Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
|
US6716830B2
(en)
*
|
1998-09-30 |
2004-04-06 |
Alcon, Inc. |
Ophthalmic antibiotic compositions containing moxifloxacin
|
US6509327B1
(en)
|
1998-09-30 |
2003-01-21 |
Alcon Manufacturing, Ltd. |
Compositions and methods for treating otic, ophthalmic and nasal infections
|
HUP0201700A3
(en)
*
|
1999-06-22 |
2003-02-28 |
Boehringer Ingelheim Int |
Stable xylometazoline and oxymetazoline solutions, their use for producing pharmaceutical compositions and pharmaceutical compositions containing them
|
FR2796553B1
(fr)
*
|
1999-07-22 |
2001-09-28 |
Warner Lambert Co |
Suspension de tixocortol pivalate, collutoire a base de celle-ci et conditionnement la contenant
|
CA2379605C
(en)
|
1999-09-24 |
2007-06-26 |
Alcon, Inc. |
Topical suspension formulations containing ciprofloxacin and dexamethasone
|
AR026073A1
(es)
|
1999-10-20 |
2002-12-26 |
Nycomed Gmbh |
Composicion farmaceutica acuosa que contiene ciclesonida
|
AU7947600A
(en)
*
|
1999-10-20 |
2001-04-30 |
Teijin Limited |
Aqueous medicinal compositions
|
AU772406B2
(en)
*
|
1999-11-18 |
2004-04-29 |
Alcon Inc. |
Use of H1 antagonist and a safe steroid to treat eye conditions
|
US20040097486A1
(en)
*
|
1999-11-18 |
2004-05-20 |
Yanni John M. |
Use of an H1 antagonist and a safe steroid to treat eye conditions
|
US6495534B2
(en)
*
|
2000-05-15 |
2002-12-17 |
Pharmacia & Upjohn Spa |
Stabilized aqueous suspensions for parenteral use
|
WO2001087262A2
(en)
*
|
2000-05-15 |
2001-11-22 |
Pharmacia Italia S.P.A. |
Stabilized steroidal suspension
|
CA2412575C
(en)
|
2000-07-26 |
2009-12-29 |
Onkar N. Singh |
Improved process for manufacturing compositions containing ciprofloxacin and hydrocortisone
|
MXPA03004241A
(es)
*
|
2000-11-15 |
2004-12-03 |
Chandavarkar Mohan A |
Preparaciones farmaceuticas que comprenden corticosteroides y agentes antiinfecciosos.
|
WO2002040030A1
(en)
*
|
2000-11-16 |
2002-05-23 |
Alcon Manufacturing, Ltd. |
Combination therapy for lowering and controlling intraocular pressure
|
DK1429780T3
(da)
*
|
2001-09-21 |
2006-02-13 |
|
Fremgangsmåde til behandling af mellemoreinfektioner
|
US7001615B1
(en)
|
2001-12-07 |
2006-02-21 |
Alcon, Inc. |
Sustained release ophthalmic, otic and nasal suspension
|
US20090215735A1
(en)
*
|
2002-02-25 |
2009-08-27 |
Alcon, Inc. |
Topical solution formulations containing a corticosteroid and a cyclodextrin
|
AU2003280960A1
(en)
*
|
2002-07-15 |
2004-02-02 |
Alcon, Inc. |
Pharmaceutical compositions for otic use
|
AU2003301263A1
(en)
*
|
2002-10-18 |
2004-05-04 |
Joel S. Echols |
Three layer tear formulation
|
US20040151754A1
(en)
*
|
2002-12-20 |
2004-08-05 |
Control Delivery Systems, Inc. |
Steroid suspensions for intraocular use
|
CN100341498C
(zh)
|
2003-01-21 |
2007-10-10 |
千寿制药株式会社 |
含有2-氨基-3-(4-溴苯甲酰基)苯乙酸的水成液制剂
|
US20050069590A1
(en)
*
|
2003-09-30 |
2005-03-31 |
Buehler Gail K. |
Stable suspensions for medicinal dosages
|
US20050197303A1
(en)
*
|
2003-10-31 |
2005-09-08 |
Bausch & Lomb Incorporated |
Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
|
US20050095205A1
(en)
*
|
2003-10-31 |
2005-05-05 |
Ramesh Krishnamoorthy |
Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
|
CN100450488C
(zh)
*
|
2003-11-03 |
2009-01-14 |
诺顿·希尔思凯尔有限公司 |
用于干粉吸入剂的软类固醇组合物
|
US20050101582A1
(en)
*
|
2003-11-12 |
2005-05-12 |
Allergan, Inc. |
Compositions and methods for treating a posterior segment of an eye
|
US20070224278A1
(en)
*
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
US20060141049A1
(en)
*
|
2003-11-12 |
2006-06-29 |
Allergan, Inc. |
Triamcinolone compositions for intravitreal administration to treat ocular conditions
|
US20080306039A1
(en)
*
|
2003-12-02 |
2008-12-11 |
Keiichi Matsuhisa |
Loteprednol Etabonate Aqueous Suspension
|
PE20050941A1
(es)
|
2003-12-16 |
2005-11-08 |
Nycomed Gmbh |
Suspensiones acuosas de ciclesonida para nebulizacion
|
AU2005209201B2
(en)
*
|
2004-01-20 |
2010-06-03 |
Allergan, Inc. |
Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
|
EP1713514B1
(de)
*
|
2004-01-28 |
2021-11-24 |
Johns Hopkins University |
Arzneimittel und genträgerteilchen, die sich schnell durch schleimhautbarrieren bewegen
|
US20050182039A1
(en)
*
|
2004-02-13 |
2005-08-18 |
Bausch & Lomb Incorporated |
Use of Loteprednol etabonate for the treatment of dry eye
|
AU2005229006B9
(en)
*
|
2004-03-25 |
2011-05-19 |
Bausch & Lomb Incorporated |
Use of loteprednol etabonate for the treatment of dry eye
|
US20050234018A1
(en)
*
|
2004-04-15 |
2005-10-20 |
Allergan, Inc. |
Drug delivery to the back of the eye
|
US8119154B2
(en)
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
US8147865B2
(en)
*
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
BRPI0513243B8
(pt)
*
|
2004-07-12 |
2021-05-25 |
Allergan Inc |
composições oftálmicas e respectivos usos
|
WO2006031848A2
(en)
*
|
2004-09-15 |
2006-03-23 |
Ivax Corporation |
Corticosteroid topical dispersion with low content of surfactant
|
WO2006043965A1
(en)
*
|
2004-10-14 |
2006-04-27 |
Allergan, Inc. |
Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
|
KR20080011311A
(ko)
*
|
2005-05-10 |
2008-02-01 |
알콘, 인코퍼레이티드 |
안과 약제, 폴록사민 및 글리콜 장성―조절제를 포함하는안과 현탁제, 안질환 치료용 의약의 제조를 위한 상기조성물의 용도
|
DK1885336T3
(da)
*
|
2005-05-10 |
2009-05-25 |
Alcon Inc |
Suspensionsformuleringer, der omfatter et aktivt princip, et overfladeaktivt poloxamer- eller meroxapolmiddel og en glycol, samt deres anvendelse til fremstilling af et medikament til behandling af öjenlidelser
|
EP1928439A4
(de)
*
|
2005-09-26 |
2009-04-29 |
Piedmont Pharmaceuticals Llc |
Verfahren zur behandlung und prävention von otitis media mit chemischen penetrationsverstärkern zur erleichterung der transmembranösen arzneiabgabe in das mittelohr
|
WO2007037886A2
(en)
*
|
2005-09-26 |
2007-04-05 |
Piedmont Pharmaceuticals Llc |
Methods for treatment and prevention of otitis media using nonionic surfactants to facilitate transmembrane drug delivery into the middle ear
|
MX339797B
(es)
|
2005-10-18 |
2016-06-10 |
Allergan Inc |
Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.
|
US20090082321A1
(en)
*
|
2007-09-21 |
2009-03-26 |
Allergan, Inc. |
Steroid containing drug delivery systems
|
US20070093461A1
(en)
*
|
2005-10-26 |
2007-04-26 |
Bausch & Lomb Incorporated |
Effect of Loteprednol etabonate on vascular dysfunction
|
US20070110812A1
(en)
*
|
2005-11-14 |
2007-05-17 |
Bausch & Lomb Incorporated |
Ophthalmic composition for dry eye therapy
|
US7955632B2
(en)
*
|
2005-12-07 |
2011-06-07 |
Bayer B.V. |
Process for manufacturing chewable dosage forms for drug delivery and products thereof
|
US20070128251A1
(en)
*
|
2005-12-07 |
2007-06-07 |
Piedmont Pharmaceuticals, Inc. |
Process for manufacturing chewable dosage forms for drug delivery and products thereof
|
KR20170123724A
(ko)
|
2006-03-28 |
2017-11-08 |
자블린 파머슈티칼스 인코포레이티드 |
저 투여량의 디클로페낙 및 베타-사이클로덱스트린 제형
|
KR20090010953A
(ko)
*
|
2006-03-28 |
2009-01-30 |
자블린 파머슈티칼스 인코포레이티드 |
저 복용량의 비-스테로이드성 항염증성 약물 및 베타-사이클로덱스트린 제형
|
US20070238789A1
(en)
*
|
2006-03-31 |
2007-10-11 |
Chin-Ming Chang |
Prednisolone acetate compositions
|
WO2008002118A1
(es)
*
|
2006-06-27 |
2008-01-03 |
Arturo Jimenez Bayardo |
Una formulación oftálmica en suspensión de etabonato de loteprednol y clorhidrato de ciprofloxacina
|
ES2577390T3
(es)
|
2006-07-21 |
2016-07-14 |
Biodelivery Sciences International, Inc. |
Dispositivos de administración transmucosa con mayor captación
|
WO2008027341A2
(en)
*
|
2006-08-30 |
2008-03-06 |
Merck & Co., Inc. |
Topical ophthalmic formulations
|
WO2008027340A2
(en)
*
|
2006-08-30 |
2008-03-06 |
Merck & Co., Inc. |
Topical ophthalmic formulations
|
EP2061433B1
(de)
*
|
2006-09-08 |
2011-02-16 |
Johns Hopkins University |
Zusammensetzungen zur transportintensivierung durch die schleimhaut
|
TWI415629B
(zh)
*
|
2006-10-26 |
2013-11-21 |
Otsuka Pharma Co Ltd |
含有瑞巴匹特之水性醫藥懸浮物及其製造方法
|
EP2089036A1
(de)
*
|
2006-11-02 |
2009-08-19 |
Riolan Technologies, Inc. |
Verfahren zur behandlung einer augenallergie mit niedrig dosiertem dexamethason
|
US20090023668A1
(en)
*
|
2006-11-02 |
2009-01-22 |
Friedlaender Mitchell H |
Method for treating blepharitis
|
CN101721714B
(zh)
*
|
2009-12-18 |
2011-12-07 |
重庆莱美药业股份有限公司 |
实体瘤被动靶向性抗癌前药及其制备方法
|
WO2011106702A2
(en)
|
2010-02-25 |
2011-09-01 |
The Johns Hopkins University |
Sustained delivery of therapeutic agents to an eye compartment
|
US10307372B2
(en)
|
2010-09-10 |
2019-06-04 |
The Johns Hopkins University |
Rapid diffusion of large polymeric nanoparticles in the mammalian brain
|
JP2014512387A
(ja)
*
|
2011-04-22 |
2014-05-22 |
アルコン リサーチ, リミテッド |
二つの異なる粘性増強剤を有する粘性増強システムを備えた眼科用組成物
|
CA2845634C
(en)
|
2011-08-18 |
2021-07-13 |
Biodelivery Sciences International, Inc. |
Abuse-resistant mucoadhesive devices for delivery of buprenorphine
|
AU2012312816A1
(en)
|
2011-09-22 |
2014-04-24 |
Bausch & Lomb Incorporated |
Ophthalmic gel compositions
|
US9901539B2
(en)
|
2011-12-21 |
2018-02-27 |
Biodelivery Sciences International, Inc. |
Transmucosal drug delivery devices for use in chronic pain relief
|
WO2013138346A1
(en)
|
2012-03-16 |
2013-09-19 |
The Johns Hopkins University |
Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
|
AU2013232297B2
(en)
|
2012-03-16 |
2016-01-14 |
The Johns Hopkins University |
Controlled release formulations for the delivery of HIF-1 inhibitors
|
EP4008355A1
(de)
|
2012-05-03 |
2022-06-08 |
Kala Pharmaceuticals, Inc. |
Pharmazeutische nanopartikel mit verbessertem mukosalem transport
|
WO2013166408A1
(en)
*
|
2012-05-03 |
2013-11-07 |
Kala Pharmaceuticals, Inc. |
Pharmaceutical nanoparticles showing improved mucosal transport
|
EP2844223A1
(de)
*
|
2012-05-03 |
2015-03-11 |
Kala Pharmaceuticals, Inc. |
Pharmazeutische nanopartikel mit verbessertem mukosalem transport
|
US11596599B2
(en)
|
2012-05-03 |
2023-03-07 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
US9827191B2
(en)
*
|
2012-05-03 |
2017-11-28 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
EP2849728A1
(de)
|
2012-05-04 |
2015-03-25 |
The Johns Hopkins University |
Arzneimittelträger auf lipidbasis zur schnellen penetration durch schleimauskleidungen
|
CN103565742A
(zh)
*
|
2012-07-25 |
2014-02-12 |
天津金耀集团有限公司 |
氟米龙滴眼液
|
CN103565740A
(zh)
*
|
2012-07-25 |
2014-02-12 |
天津金耀集团有限公司 |
依碳氯替泼诺混悬滴眼液
|
US10568975B2
(en)
|
2013-02-05 |
2020-02-25 |
The Johns Hopkins University |
Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
|
AU2014216178B2
(en)
|
2013-02-15 |
2018-06-28 |
KALA BIO, Inc. |
Therapeutic compounds and uses thereof
|
ES2831625T3
(es)
|
2013-02-20 |
2021-06-09 |
Kala Pharmaceuticals Inc |
Compuestos terapéuticos y sus usos
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
US20150164882A1
(en)
|
2013-07-22 |
2015-06-18 |
Imprimis Pharmaceuticals, Inc. |
Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
|
US20160279055A1
(en)
|
2013-07-22 |
2016-09-29 |
Imprimis Pharmaceuticals, Inc. |
Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
|
JP6426194B2
(ja)
|
2013-11-01 |
2018-11-21 |
カラ ファーマシューティカルズ インコーポレイテッド |
治療用化合物の結晶形態及びその使用
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
RS63304B1
(sr)
*
|
2014-11-07 |
2022-07-29 |
Santen Pharmaceutical Co Ltd |
Oftalmološka vodena kompozicija
|
EP3250184A1
(de)
|
2015-01-27 |
2017-12-06 |
The Johns Hopkins University |
Hypotone hydrogelformulierungen für den verbesserten transport von wirkstoffen an schleimhautoberflächen
|
CN106279324A
(zh)
*
|
2015-05-27 |
2017-01-04 |
天津金耀集团有限公司 |
依碳氯替泼诺一水合物及其晶型与制备方法
|
CN106279325A
(zh)
*
|
2015-05-27 |
2017-01-04 |
天津金耀集团有限公司 |
一种依碳氯替泼诺新晶型及其制备方法
|
CN106892952A
(zh)
*
|
2015-12-21 |
2017-06-27 |
天津金耀集团有限公司 |
一种依碳氯替泼诺新晶型及其制备方法
|
CN106892953A
(zh)
*
|
2015-12-21 |
2017-06-27 |
天津金耀集团有限公司 |
依碳氯替泼诺一水合物及其晶型与制备方法
|
BR112019004463A2
(pt)
|
2016-09-08 |
2019-05-28 |
Kala Pharmaceuticals Inc |
formas cristalinas de compostos terapêuticos, seus processos de obtenção e seus métodos de uso
|
EP3509422A4
(de)
|
2016-09-08 |
2020-05-20 |
Kala Pharmaceuticals, Inc. |
Kristalline formen von therapeutischen verbindungen und verwendungen davon
|
US10392399B2
(en)
|
2016-09-08 |
2019-08-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|